From study startup to live Alzheimer's recruitment in 10 days.

Leapcure reaches Alzheimer's patients through the caregiver organizations and grassroots communities families actually trust, and educates caregivers before site referral, so your sites receive enrollment-ready patients, not volume they cannot absorb.

Talk to our Alzheimer's teamSee how it works →
6,000+
Alzheimer's patients engaged
for a Phase 3 study
32+
Advocacy and caregiver communities
activated
1.5 days
Median between referral and site follow-up
63%
Increase in screened patients
after Leapcure involvement

Understanding Alzheimer's Disease as a Clinical Trial Indication

Alzheimer's disease is a progressive neurodegenerative condition, and the decision to join a trial is rarely made by the patient alone. Caregivers and families coordinate specialist care, manage day-to-day functioning, and weigh study options together, often while navigating progressive memory loss. Any recruitment approach that does not account for the caregiver is working against how these decisions are actually made.

Alzheimer's is also one of the most competitive indications in research. More than a thousand Alzheimer's studies are recruiting worldwide at any given time, many backed by well-funded sponsors with global sites. Eligibility is tightly tied to disease stage and medical history, visit schedules and travel can be hard to manage in memory-sensitive situations, and sites are easily overwhelmed when a recruitment vendor sends high referral volume with mismatched expectations. Standing out requires reaching families where they already are and arriving prepared.

Leapcure recruits Alzheimer's patients through the caregiver organizations and grassroots communities families already trust, educates caregivers before any patient is assigned to a site, and weights campaigns toward the sites with capacity to follow up. On a recent Phase 3 Alzheimer's agitation study, that model went live in ten days and contributed efficiently to enrollment on a limited media budget. Alzheimer's is exactly the kind of caregiver-mediated problem that model is built for.

The Challenge

Alzheimer's recruitment is caregiver-mediated, highly competitive, and easy to get wrong. Reaching families where they already are, and arriving prepared, is what separates referrals a site can use from volume it cannot absorb.

Enrollment decisions are made with caregivers, not alone

Caregivers and families coordinate specialist care, manage daily functioning, and weigh study options together, often while navigating progressive memory loss. A recruitment approach that does not account for the caregiver is working against how these decisions are actually made.

We educate caregivers on what participation involves before any patient is assigned to a site, so the families who arrive are prepared.

One of the most competitive indications in research

More than a thousand Alzheimer's studies are recruiting worldwide at any given time, many backed by well-funded sponsors with global sites. Standing out requires reaching families through the communities they already trust, not louder generic advertising.

On a Phase 3 Alzheimer's agitation study we engaged more than 6,000 patients and drove a 63% increase in screened patients after getting involved.

Sites are easily overwhelmed by mismatched referral volume

When a vendor sends high referral volume with mismatched expectations, sites are flooded with patients they cannot absorb. Preparation before site assignment matters as much as reach.

We weight campaigns toward the sites with capacity to follow up, with a 1.5-day median between referral and site follow-up.

Memory-sensitive logistics complicate participation

Eligibility is tightly tied to disease stage and medical history, and visit schedules and travel can be hard to manage in memory-sensitive situations. These realities have to be handled before a patient ever reaches a site.

We can go live in 10 days and account for disease stage and visit-schedule burden through a caregiver-inclusive process before site assignment.

One Caregiver-Led Strategy for Your Alzheimer's Trial

Every Alzheimer's study is different. Leapcure deploys the right mix of caregiver outreach, grassroots partnerships, and precision digital, mapped to your protocol, your sites, and your timeline.

1

Launch fast

We can go live in as little as 10 days from study startup, activating caregiver organizations, grassroots communities, and digital campaigns weighted toward the sites with capacity to follow up.

2

Educate caregivers and pre-screen before site assignment

Every patient is engaged through a caregiver-inclusive, memory-sensitive process before site assignment. We assess protocol eligibility, account for disease stage and visit-schedule burden, and make sure caregivers understand what participation involves. Sites conduct official screening; we ensure the families who arrive are prepared.

3

Optimize on site capacity and engagement

Channel performance, referral quality, and site follow-up are tracked continuously and rebalanced weekly, with volume directed to the sites best able to absorb it.

Phase 3 Alzheimer's Recruitment, Live in 10 Days

Challenge Context

Indication

Alzheimer's disease, agitation, Phase 3 (mild-to-moderate). Presented as the proof case for our broader Alzheimer's model.

Sites

Multiple active sites.

Challenge

A highly competitive landscape with 1000+ Alzheimer's studies recruiting; varying patient interest typical of an agitation study; caregiver-mediated enrollment decisions; and sites at risk of being overwhelmed by referral volume carrying mismatched expectations.

Channels Deployed

Digital advertising, caregiver organizations, and grassroots partnerships, with campaigns weighted toward sites with capacity, and caregiver education delivered before site assignment.

Results & Metrics

Enrollments

Leapcure delivered 15 of the study's 50 enrollments (30%) over a four-month window.

Active-window contribution

During the period Leapcure was actively recruiting, that work represented roughly half of all enrollments. The full-study figure (15 of 50) and the active-window figure (about 50%) describe two different time periods, not two versions of the same number.

Screened patients

63% increase in the number of screened patients after Leapcure's involvement.

Speed

Live in 10 days from study startup, with a 1.5-day median between referral and site follow-up.

Reach and efficiency

6,000+ Alzheimer's patients engaged; 42+ referrals per month on a limited media budget.

Cost efficiency in this program

Approximately $500K saved versus the client's benchmark. Acquisition cost varies by protocol, phase, site selection, and channel mix; this reflects the specific requirements of this program, not a standard rate.

Built Around the Caregiver, Proven in Alzheimer's

Leapcure reaches Alzheimer's families through caregiver organizations and grassroots communities, precision digital weighted to site capacity, caregiver education before site assignment, and answer-engine visibility delivered to your trial.

Caregiver Organizations and Grassroots Communities

  • •We reach Alzheimer's families through caregiver-focused organizations and grassroots communities they already trust, including caregiver-specific networks, not cold lists.
  • •Content is co-developed with community partners so research arrives as a trusted option, and we go where families actually engage, not only the largest-name org.

Precision Digital, Weighted to Site Capacity

  • •Search and social campaigns optimized for Alzheimer's patients and caregivers, targeted by geography and disease stage.
  • •Campaigns are weighted toward the sites with capacity to follow up, which was a key driver of enrollment efficiency in our Phase 3 program.

Caregiver Education Before Site Assignment

  • •Every referred patient is supported through a caregiver-inclusive process, and caregivers are educated on what participation involves before the patient is assigned to a site.
  • •This is the difference between a site receiving prepared families and a site being flooded with referrals that carry mismatched expectations. It is the mechanism behind our referral quality and fast site follow-up.

AEO / AI-Search Visibility for Your Trial

  • •Patients and caregivers increasingly ask AI assistants what Alzheimer's trials they may be eligible for.
  • •We make the trial's information genuinely retrievable through clean server-rendered structure, first-party authority (real data, sourced statistics, named reviewer, last-updated date), and presence in trusted third-party sources such as advocacy organizations and ClinicalTrials.gov.

Built on Trusted Relationships in the Alzheimer's and Caregiver Community

Leapcure's Alzheimer's advocacy and caregiver partnerships are active and co-developed, not list purchases.

Alzheimer's News Today

Engaged Alzheimer's patient and caregiver media community

National Alliance for Caregiving

Caregiver-focused network, central to caregiver-mediated enrollment

Dementia Society of America

National dementia awareness and patient support organization

MindMate

Digital platform for people living with dementia and their families

AAGP (American Association for Geriatric Psychiatry)

Clinical community relevant to agitation and behavioral symptoms

Alzheimer's Association

Largest Alzheimer's patient and caregiver organization

Living with Alzheimer's, or caring for someone who is? A clinical trial may be an option.

If you or someone you love is living with Alzheimer's, a clinical trial may offer access to investigational treatments not yet widely available. We know these decisions are rarely made alone, and that daily life can already feel full, between memory changes, appointments, and coordinating care. Leapcure supports patients and caregivers together, at your pace, and helps your family explore whether a study might be a fit, keeping the patient's needs at the forefront.

See if a trial may be right for you
Leapcure kangaroo mascot

Leapcure's Alzheimer's recruitment team has completed a Phase 3 Alzheimer's program, live in 10 days, delivering 42+ referrals a month on a limited media budget with a 1.5-day median referral-to-follow-up, through a caregiver-centered model built around how Alzheimer's enrollment decisions are actually made. We can mobilize quickly and adapt the channel mix to your protocol.

Talk to our Alzheimer's team